Biotech of the Week: Pharnext, developing next level drugs against Alzheimer’s and Parkinson’s disease

27/05/2016 - 2 minutes

The Scandinavian charm is wonderful but this week we are (finally) heading back to Central Europe. Do I really need to say what happens in Paris? We all know that: The Eiffel Tower, the Louvre, the pretty sights, la Seine and it’s also the cité de l’amour. However, it is also where Pharnext, our Biotech of the Week, is based.

pharnext_logo_biotech_week

City: Paris (France)

Founded: 2007

Employees: 35

Financial Data: €65M Total Raised (as of 12/2015)

Related Content

CEO: Daniel Cohen

daniel_cohen_ceo_pharnext_biotech_week

Mission: Based in the Parisian suburban area of Issy-le-Moulineaux, Pharnext is an advanced clinical stage biopharmaceutical company aiming at developing new therapeutics that targets simultaneously multiple key disease pathways for the severe orphan and common neurological diseases. With an R&D platform based on networking pharmacology, this allows the development of synergistic combinations and compositions of drugs – also known as pleodrugs –

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member